Effects of Telmisartan on Recurrence of Paroxysmal Atrial Fibrillation and Serum Levels of C Reaction Protein in Patients with Hypertension Combined with Paroxysm Atrial Fibrillation_West China Medical Journal

Authors：

1. Department of Cardiology, Hospital of Sichuan Petroleum Administration, Chengdu, Sichuan 610213, P. R. China; 2. Department of Cardiology, People’s Hospital of Suining, Suining, Shichuan 629000, P. R. China;

Corresponding author：

Keywords：

替米沙坦; 高敏C反应蛋白; 心房颤动

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】目的 观察替米沙坦对高血压伴阵发性心房颤动患者房颤复发及对左心房内径(LAD)、血清C反应蛋白(HsCRP) 的影响。方法 2007年6月-2008年12月阵发性房颤患者42例，随机分为替米沙坦组和常规治疗组各21例，分别于治疗前、治疗后12个月测定LAD、HsCRP水平，并随访治疗后12个月时房颤复发次数。结果替米沙坦组房颤复发次数及LAD、HsCRP水平均低于常规治疗组，两组比较，有统计学意义(P lt;0.05)。结论替米沙坦能抑制高血压伴阵发性房颤患者的左房重构，降低HsCRP水平，减少房颤复发。
【Abstract】 Objective To explore the effects of Telmisartan on recurrence of paroxysmal atrial fibrillation (PAF), left atrial direction (LAD) and serum levels of high sensitivity C reaction protein (HsCRP) in patients with hypertension combined with paroxysm atrial fibrillation. Methods A total of 42 PAF patients from June 2007 to December 2008 were randomly divided into Telmisartan group and routine treatment group. Before the treatment and 12 months after the treatment, LAD and HsCRP were detected,and the recurrence times of atrial fibrillation were counted 12 months after the treatment. Results The recurrence times of atrial fibrillation, and the levels of LAD and HsCRP were significant lower in Telmisartan group than that in the routine treatment group (P lt;0.05). Conclusion Telmisartan can reduce the recurrence of PAF and the levels of LAD and HsCRP.

Citation： WANG Xinqun,DENG Xuejun. Effects of Telmisartan on Recurrence of Paroxysmal Atrial Fibrillation and Serum Levels of C Reaction Protein in Patients with Hypertension Combined with Paroxysm Atrial Fibrillation. West China Medical Journal, 2010, 25(9): 1592-1593. doi: Copy

1.	Aviles RJ, Martin DO, Apperson HC, et al. Inflammation as a risk factor for atrialfibrillation[J]. Circulation, 2003, 108(24): 3006-3010.
2.	Healery JS, Morillo CA, Connooly SJ. Role of the reninangiotensin-aldosterone system in atrial fibrillation and cardiac remodeling[J]. Cur Opin Cardiol, 2005, 20(1): 31-37.
3.	Watanabe E, Arakawa T, Uchiyama T, et al. High sensitivity C reaction protein is predictive of succesful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol, 2006, 108(3): 346-353.
4.	Dernellis JM, Paneratou MP. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004, 25(13): 1100-1107.
5.	Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: result from the Valsartan heart failure trial[J]. Am Heart J, 2005, 149(3): 548.
6.	Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation[J]. Cardiovas Res, 2002, 54(2): 230-246.

1. Aviles RJ, Martin DO, Apperson HC, et al. Inflammation as a risk factor for atrialfibrillation[J]. Circulation, 2003, 108(24): 3006-3010.
2. Healery JS, Morillo CA, Connooly SJ. Role of the reninangiotensin-aldosterone system in atrial fibrillation and cardiac remodeling[J]. Cur Opin Cardiol, 2005, 20(1): 31-37.
3. Watanabe E, Arakawa T, Uchiyama T, et al. High sensitivity C reaction protein is predictive of succesful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion[J]. Int J Cardiol, 2006, 108(3): 346-353.
4. Dernellis JM, Paneratou MP. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004, 25(13): 1100-1107.
5. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: result from the Valsartan heart failure trial[J]. Am Heart J, 2005, 149(3): 548.
6. Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation[J]. Cardiovas Res, 2002, 54(2): 230-246.

West China Medical Journal

Effects of Telmisartan on Recurrence of Paroxysmal Atrial Fibrillation and Serum Levels of C Reaction Protein in Patients with Hypertension Combined with Paroxysm Atrial Fibrillation

Abstract Full text Figures/Tables Video References Cited by

Format

Content